Pharmala Biotech Holdings Inc.
MDMA
CNSX
| 02/28/2025 | 11/30/2024 | 08/31/2024 | 05/31/2024 | 02/29/2024 | |
|---|---|---|---|---|---|
| Revenue | 284.50K | 224.10K | 733.50K | 1.02M | 921.60K |
| Total Other Revenue | -- | -- | -- | -- | -- |
| Total Revenue | 284.50K | 224.10K | 733.50K | 1.02M | 921.60K |
| Cost of Revenue | -99.40K | -106.00K | 108.60K | 276.00K | 273.10K |
| Gross Profit | 383.80K | 330.10K | 625.00K | 748.40K | 648.70K |
| SG&A Expenses | 1.48M | 1.08M | 906.40K | 969.10K | 819.30K |
| Depreciation & Amortization | 70.10K | 61.50K | 51.60K | 44.80K | 42.90K |
| Other Operating Expenses | -- | -- | -- | -- | -- |
| Total Operating Expenses | 1.57M | 1.12M | 1.16M | 1.34M | 1.18M |
| Operating Income | -1.29M | -894.70K | -425.10K | -313.90K | -257.50K |
| Income Before Tax | -1.38M | -981.00K | -606.00K | -502.50K | -448.90K |
| Income Tax Expenses | -- | -- | -- | -- | -- |
| Earnings from Continuing Operations | -1.38 | -0.98 | -0.61 | -0.50 | -0.45 |
| Earnings from Discontinued Operations | -- | -- | -- | -- | -- |
| Extraordinary Item & Accounting Change | -- | -- | -- | -- | -- |
| Minority Interest in Earnings | -- | -- | -- | -- | -- |
| Net Income | -1.38M | -981.00K | -606.00K | -502.50K | -448.90K |
| EBIT | -1.29M | -894.70K | -425.10K | -313.90K | -257.50K |
| EBITDA | -1.27M | -869.40K | -398.00K | -290.00K | -224.20K |
| EPS Basic | -0.01 | -0.01 | -0.01 | -0.01 | -0.01 |
| Normalized Basic EPS | -0.01 | -0.01 | 0.00 | 0.00 | 0.00 |
| EPS Diluted | -0.01 | -0.01 | -0.01 | -0.01 | -0.01 |
| Normalized Diluted EPS | -0.01 | -0.01 | 0.00 | 0.00 | 0.00 |
| Average Basic Shares Outstanding | 371.24M | 356.39M | 354.29M | 351.65M | 345.50M |
| Average Diluted Shares Outstanding | 371.24M | 356.39M | 356.23M | 353.58M | 347.43M |
| Dividend Per Share | -- | -- | -- | -- | -- |
| Payout Ratio | -- | -- | -- | -- | -- |